Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184
Harbour BioMed and Sinopharm establish innovation R&D consortium
Active Biotech doses first patient in amended tasquinimod myelofibrosis study
Bio-Thera Solutions reports first patient dosed in Phase 1 study of BAT8013
EU approves AstraZeneca's Etcamah combination for 1st-line ER-positive advanced breast cancer
BeOne Medicines expands US manufacturing with USD300m investment
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
Greenwich LifeSciences secures UK approval to expand Phase III breast cancer trial
Elephas Biosciences partners with Invitrocue to promote elive platform in Singapore and Malaysia
Lupin spins out two oncology programmes to Kaveri Therapeutics
Fuse Oncology launches new prescribing and treatment-intent solution FuseRx
Tempus agrees to acquire Personalis in USD1.5bn precision oncology deal
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026